JPH0466453B2 - - Google Patents

Info

Publication number
JPH0466453B2
JPH0466453B2 JP60016085A JP1608585A JPH0466453B2 JP H0466453 B2 JPH0466453 B2 JP H0466453B2 JP 60016085 A JP60016085 A JP 60016085A JP 1608585 A JP1608585 A JP 1608585A JP H0466453 B2 JPH0466453 B2 JP H0466453B2
Authority
JP
Japan
Prior art keywords
cells
cancer
differentiation
present
anticancer agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60016085A
Other languages
English (en)
Japanese (ja)
Other versions
JPS61176523A (ja
Inventor
Teruhiko Betsupu
Yasushi Iwamoto
Minoru Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP60016085A priority Critical patent/JPS61176523A/ja
Priority to US06/821,973 priority patent/US4690918A/en
Priority to EP86101047A priority patent/EP0196415B1/en
Priority to DE8686101047T priority patent/DE3682091D1/de
Publication of JPS61176523A publication Critical patent/JPS61176523A/ja
Publication of JPH0466453B2 publication Critical patent/JPH0466453B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP60016085A 1985-01-30 1985-01-30 制癌剤 Granted JPS61176523A (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP60016085A JPS61176523A (ja) 1985-01-30 1985-01-30 制癌剤
US06/821,973 US4690918A (en) 1985-01-30 1986-01-24 Use of trichostatin compounds for treating tumor cells
EP86101047A EP0196415B1 (en) 1985-01-30 1986-01-27 Trichostatins a and c as antitumour drugs
DE8686101047T DE3682091D1 (de) 1985-01-30 1986-01-27 Trichostatine a und c als antikrebsmittel.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60016085A JPS61176523A (ja) 1985-01-30 1985-01-30 制癌剤

Publications (2)

Publication Number Publication Date
JPS61176523A JPS61176523A (ja) 1986-08-08
JPH0466453B2 true JPH0466453B2 (enExample) 1992-10-23

Family

ID=11906699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60016085A Granted JPS61176523A (ja) 1985-01-30 1985-01-30 制癌剤

Country Status (4)

Country Link
US (1) US4690918A (enExample)
EP (1) EP0196415B1 (enExample)
JP (1) JPS61176523A (enExample)
DE (1) DE3682091D1 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0775593A (ja) * 1993-09-08 1995-03-20 Suntory Ltd 蛋白質の製造方法
EP0827946A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Inhibitors for the differentiation of cells, in particular hepatic stellate cells
ES2195196T3 (es) * 1996-12-30 2003-12-01 Univ Johns Hopkins Med Determinacion de la propensidad de un organo o un tejido al cancer por determinacion de su patron de impresion.
EP1332756A3 (en) * 1996-12-30 2003-12-10 The Johns Hopkins University School Of Medicine Compositions and methods for restoring a normal pattern of imprinting to cells
US6387673B1 (en) * 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6518012B1 (en) 1999-04-02 2003-02-11 Health Research, Inc. Method for regulating the expression of MHC antigens and CD40 by inhibitors of histone deacetylation
US6544957B2 (en) 2000-01-04 2003-04-08 The Johns Hopkins University Methods and reagents for facilitating transcription
WO2002055017A2 (en) * 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) * 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
EP1249246B1 (en) * 2001-04-10 2005-09-28 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of an histone deacetylase inhibitor for the treatment of diseases associated with an hpv infection
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
AU2002315166A1 (en) * 2001-06-15 2003-01-02 The Trustees Of Columbia University In The City Of New York Sir2alpha-based therapeutic and prophylactic methods
US20040087657A1 (en) * 2001-10-16 2004-05-06 Richon Victoria M. Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20030147813A1 (en) * 2002-02-07 2003-08-07 John Lyons Method for treating chronic myelogenous leukemia
EP1482962A4 (en) * 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
EP1485076A1 (en) * 2002-02-27 2004-12-15 The Ohio State University Research Foundation Therapeutic methods for acute myeloid leukemia
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
RU2394022C2 (ru) * 2002-03-04 2010-07-10 МЕРК ЭйчДиЭйСи Рисерч, ЛЛС Способы индукции конечной дифференцировки
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
WO2003088954A1 (en) * 2002-04-15 2003-10-30 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US20040162263A1 (en) * 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
WO2005000332A2 (en) 2003-06-27 2005-01-06 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
RU2356547C2 (ru) * 2003-08-26 2009-05-27 Мерк ЭйчДиЭйСи Рисерч ЛЛС Способы лечения рака с использованием ингибиторов hdac
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
US7875275B2 (en) * 2004-06-16 2011-01-25 The General Hospital Corporation Use of Bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
US7250416B2 (en) * 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
TWI415603B (zh) * 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
EP1924245A2 (en) * 2005-08-19 2008-05-28 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070117776A1 (en) * 2005-11-04 2007-05-24 John Lyons Low Dose Therapy Of DNA Methylation Inhibitors
CA2627129A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer
CA2622136A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and erlotinib for treating cancer
US20070105792A1 (en) * 2005-11-04 2007-05-10 Dimartino Jorge F Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
JP2007262058A (ja) * 2006-03-03 2007-10-11 Tokyo Univ Of Science 糸状菌の分化抑制剤
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
WO2008042795A2 (en) * 2006-09-29 2008-04-10 The Board Of Trustees Of The University Of Illinois Histone acetyle transferase activators and histone deacetylase inhibitors in the treatment of alcoholism
AU2007317921A1 (en) * 2006-11-03 2008-05-15 University Of Maryland, Baltimore Methods of using SAHA and Bortezomib for treating multiple myeloma
MX2009008347A (es) 2007-02-06 2009-10-19 Lixte Biotechnology Holdings I Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
US8043804B2 (en) * 2007-05-23 2011-10-25 The Trustees Of Columbia University In The City Of New York DBC1, a novel native inhibitor of anti-aging protein SIRT1
EP2185173A4 (en) * 2007-08-03 2011-01-12 Lixte Biotechnology Inc USE OF PHOSPHATASES FOR THE TREATMENT OF NEUROBLASTOMES AND MEDULLOGASTOMES
US8143445B2 (en) * 2007-10-01 2012-03-27 Lixte Biotechnology, Inc. HDAC inhibitors
EP2309853A4 (en) * 2008-08-01 2012-04-25 Lixte Biotechnology Inc METHOD FOR CELL MITITULATING BY INHIBITION OF SERIN / THREONINE PHOSPHATASE
US8227473B2 (en) * 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US8058268B2 (en) * 2008-08-01 2011-11-15 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
CN108635367B (zh) 2011-08-30 2020-08-21 阿斯泰克斯制药公司 地西他滨衍生物制剂
MX2015014249A (es) 2013-04-09 2016-06-02 Lixte Biotechnology Inc Formulaciones de oxabicicloheptanos y oxabicicloheptenos.
AU2014308704B2 (en) * 2013-08-22 2019-10-10 Vanda Pharmaceuticals Inc. Multiple myeloma treatment
JP2016528297A (ja) 2013-08-22 2016-09-15 ヴァンダ ファーマシューティカルズ インコーポレイテッド 癌治療
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
CA2991167A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
DK3429603T3 (da) 2016-03-15 2022-03-14 Childrens Medical Center Fremgangsmåder og sammensætninger vedrørende ekspansion af hæmatopoietiske stamceller
CA3046515A1 (en) 2016-12-08 2018-06-14 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
JP2020529409A (ja) 2017-08-03 2020-10-08 大塚製薬株式会社 薬物化合物およびその精製方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218478A (en) * 1979-01-05 1980-08-19 Ruiko Oiwa Trichostatin as an antiprotozoal agent
JPS60149520A (ja) * 1984-01-13 1985-08-07 Ajinomoto Co Inc 抗腫瘍剤

Also Published As

Publication number Publication date
JPS61176523A (ja) 1986-08-08
US4690918A (en) 1987-09-01
EP0196415B1 (en) 1991-10-23
DE3682091D1 (de) 1991-11-28
EP0196415A3 (en) 1988-09-07
EP0196415A2 (en) 1986-10-08

Similar Documents

Publication Publication Date Title
JPH0466453B2 (enExample)
US5244922A (en) Methods for treating viral infections
KR100196368B1 (ko) 아폽토시스 조정제
CA2213322C (en) Thiols to promote hematopoietic progenitor cell growth
Chu et al. Paeoniflorin attenuates schistosomiasis japonica-associated liver fibrosis through inhibiting alternative activation of macrophages
Poydock et al. Inhibiting effect of vitamins C and B12 on the mitotic activity of ascites tumors
RU2197984C1 (ru) Способ лечения различных форм туберкулеза легких, в том числе резистентных к противотуберкулезной химиотерапии
CN111803482A (zh) 鹿茸单体在制备抑制乳腺肿瘤骨转移的药物中的应用及药物
EP0476391B1 (en) Anti-AIDS virus composition containing cepharanthine as active compound
WO2023097764A1 (zh) 青蒿素在靶向抑制髓系来源的抑制性细胞及其在制备肿瘤免疫治疗药物中的应用
De Fabritiis et al. In vitro pharmacological purging of human bone marrow is enhanced by the use of lonidamine
CN117159525B (zh) Cert抑制剂在制备治疗急性髓系白血病的药物中的应用
RU2784809C2 (ru) Комбинированный продукт, содержащий дициклоплатин, и способ его получения и применения
US5750529A (en) Apoptosis regulating compostion
CN118236361A (zh) 牛磺酸联合化疗药物在制备抗肿瘤药物中的应用
CN117442738A (zh) 一种联合用药物组合物在制备预防或治疗t细胞淋巴瘤的药物中的应用
CN108403701B (zh) 二氢雷公藤红素在制备预防或治疗血液肿瘤疾病的药物中的用途
JP2002128690A (ja) アポトーシス誘導剤
JPS63107924A (ja) 抗レトロウイルス剤
JPS63267718A (ja) 抗腫瘍剤
WO1994013786A1 (en) Novel granulocytic precursor cell growth factor and method
HK1014499B (en) Methods for treating viral infections
HK1004469B (en) Apoptosis regulator
MXPA97006255A (en) Tioles to promote the growth of progenitor cells hematopoyeti